

Claim 12, line 1, change "8" to --16--.

Claim 16, line 4, change "anti-CD44 antibody sufficient to bind" to  
--agent that binds--.

**REMARKS**

Reconsideration of this application and entry of the foregoing amendments are respectfully requested.

Claim 8 has been cancelled and claims 9, 11, 12 and 16 amended to define the invention with additional clarity. That the claims have been revised/canceled should not be construed as an indication that Applicants agree with any view expressed by the Examiner. Rather, the claims have been revised/canceled merely to advance prosecution. (It will be appreciated that claim 16 as now presented essentially represents a "blending" of prior claims 8 and 16.) The Examiner is urged to enter the amendments if only to reduce significantly the issues for appeal.

Claims 8-12, 14-19 and 23-25 stand rejected under 35 U.S.C. §112, first paragraph, as allegedly being non-enabled. Withdrawal of the rejection is submitted to be in order in view of the Declaration submitted herewith, the above-noted claim revisions and the comments that follow.

This rejection appears to be based largely on a perceived lack of correlation between *in vitro* and animal model studies and *in vivo* results in patients. While